The grounded valuation ($170M market cap, $4.20/share) is based on a sustainable 2.5x EV/sales multiple applied to 2026E revenue of ~$58M, reflecting mid-cap medical device comps and adjusting for Apyx's early profitability and growth inflection. The business model is robust and differentiated, wit…
APYX Q4 2025: Aon Drives 38% Aesthetics Surge, Setting Stage for 19% Segment Growth in 2026
Apyx Medical’s Aon body contouring system fueled a record quarter, validating its integrated surgical strategy and reshaping the company’s growth profile. With Aon’s commercial launch translating into rapid adoption and a strong mix of new and upgrade customers, Apyx enters 2026 with high visibility into surgical aesthetics growth and a clear plan to expand its addressable market as GLP-1-driven demand reshapes the industry. Investors now face a business with leaner cost structure, a differentiated product platform, and new international and label expansion levers poised to unlock further upside.
Summary
- Aon Platform Anchors Growth: Integrated body contouring system rapidly accelerates adoption and market share gains.
- Cost Discipline Unlocks Flexibility: Restructuring yields leaner operations, enabling targeted investments in sales and innovation.
- Label Expansion and International Approvals: Power-assisted liposuction clearance and global registrations represent meaningful upside catalysts.
Performance Analysis
Apyx Medical delivered a record quarter, with total revenue up 35% year-over-year, propelled by a 38% jump in the surgical aesthetics segment, which now accounts for over 85% of total sales. The core driver was the commercial launch of the Aon system, a fully integrated body contouring platform that combines fat removal, tissue contraction, and electrosurgical capabilities. Management highlighted that Aon’s launch exceeded expectations across every metric, with strong pre-orders, robust demand, and a favorable mix of both upgrades (existing Renuvion users) and new customers fueling the performance.
Gross margin remained solid at 62.6%, with only a slight dip reflecting mix and geographic factors, while operating expenses were held flat year-over-year at $12 million. This cost discipline, following a prior restructuring, enabled Apyx to swing to positive adjusted EBITDA for the quarter and sharply reduce its net loss. OEM (original equipment manufacturer, contract device manufacturing) sales contributed $2.5 million, up 16%, but management reiterated the strategic shift away from OEM to focus on higher-margin surgical aesthetics.
- Aon System Launch Catalyzes U.S. Growth: Domestic sales surged nearly 50%, with Aon at the center of the commercial push.
- Recurring Revenue Momentum: Single-use handpiece sales grew alongside system placements, supporting an expanding installed base.
- Cash Burn Improvement: Operating cash use dropped to $2.5 million in Q4 and $8 million for the year, reflecting working capital benefits from Aon’s ramp.
With $31.7 million in cash and a plan to remain funded through 2027, Apyx’s financial position now supports measured investments in commercial expansion and R&D, while maintaining discipline as the business scales.
Executive Commentary
"To date, the launch of Aon and the level of incoming interest from customers submitting orders has exceeded our expectations across every metric. As we look at the market's reaction to Aon, it is clear that the reception aligns with what this technology is designed to deliver and we believe its adoption curve is still in the very early stages."
Charlie Goodwin, President and Chief Executive Officer
"We believe, based on our projections, including the uptake of the Aon platform, working capital management, and our continued strict cost controls, we will yield cash through 2027."
Matt Hill, Chief Financial Officer
Strategic Positioning
1. Aon as a Platform Play
The Aon system, an all-in-one body contouring platform, is the cornerstone of Apyx’s pivot to integrated surgical solutions. Its multifunctional approach—combining fat removal, tissue contraction, and real-time surgical adjustments—addresses surgeon workflow pain points and offers a compelling value proposition versus piecemeal competitor devices. Early feedback from both existing and new customers validates Aon’s disruptive potential and return on investment for practices.
2. Leveraging GLP-1-Driven Demand
GLP-1 drugs (weight loss medications) are reshaping aesthetic surgery demand, as millions of patients now seek interventions for skin laxity post-weight loss. Apyx’s Renuvion system, both standalone and as part of Aon, is positioned as a best-in-class solution for these patients—creating a tailwind that management believes is still in its early innings and will drive durable procedure growth for years.
3. Label Expansion and Geographic Growth
Pending FDA clearance for power-assisted liposuction will further differentiate Aon, allowing activation of new features in existing systems and launch of new handpieces. Management also outlined plans to register Aon in key international markets (Europe, Brazil, Colombia), with current sales limited to the U.S. and select FDA-accepting countries. These initiatives represent significant addressable market expansion levers for 2026 and beyond.
4. Commercial Team Buildout
Recruitment of top-tier sales talent and territory optimization are underway, enabled by Aon’s strong market positioning and the company’s broadened product suite. The new hires are expected to accelerate share gains and deepen surgeon engagement, supporting both system sales and recurring revenue streams.
5. Operational Discipline and Focus
Restructuring and cost controls have created a leaner operating model, reducing annual expenses by nearly $9 million and restoring financial flexibility. Management remains committed to measured investment, avoiding reversal of efficiency gains as the business scales.
Key Considerations
Apyx’s Q4 results mark an inflection point as the company transitions from niche device supplier to platform leader in surgical aesthetics. The combination of a differentiated product, favorable end-market trends, and operational discipline positions the business for sustained growth, but execution on international, label expansion, and salesforce ramp will be critical in 2026.
Key Considerations:
- GLP-1 Market Tailwind: Rapid adoption of weight loss drugs creates a new, high-volume patient cohort seeking body contouring procedures, directly benefiting Apyx’s Renuvion and Aon systems.
- Mix Shift to Higher-Margin Segments: Strategic focus on surgical aesthetics over OEM manufacturing is improving gross margin quality and recurring revenue visibility.
- Label Expansion Upside Not in Guidance: Power-assisted liposuction handpiece sales are excluded from 2026 guidance, representing a potential catalyst if FDA clearance is secured mid-year.
- International Registration Still Early: Aon is currently sold almost exclusively in the U.S.; global expansion is a multiyear opportunity with regulatory and commercial ramp risks.
- Sales Execution and Training: Success hinges on onboarding new sales talent and deepening surgeon practice development to accelerate adoption curves and maximize installed base utilization.
Risks
Execution on label expansion and international registration timelines remains a material risk, as regulatory delays could defer upside from new features and markets. The surgical aesthetics market is also highly competitive, with established players and evolving technologies. While Apyx’s cost discipline is a strength, aggressive hiring or marketing spend could pressure margins if not tightly managed. Finally, macroeconomic volatility or GLP-1 prescription trends could impact procedure volumes and capital equipment demand.
Forward Outlook
For Q1 and full-year 2026, Apyx guided to:
- Total revenue of $57.5 million to $58.5 million, up 9% to 11% year-over-year
- Surgical aesthetics revenue of $53 million to $54 million, up 17% to 19%
- OEM revenue of approximately $4.5 million, down from $7.5 million in 2025
- Gross margin of 61% to 62%, with operating expenses capped at $45 million
Management emphasized that guidance excludes any contribution from power-assisted liposuction handpieces, which would be incremental if FDA clearance is secured mid-2026. The business is expected to be cash flow positive by Q4 2026, with cash runway through 2027 based on current projections.
- Guidance assumes continued ramp of Aon platform and strict cost control
- International and label expansion represent upside not factored into the base case
Takeaways
Apyx’s transformation is anchored by Aon’s commercial success and a sharpened focus on surgical aesthetics, while cost discipline and cash runway provide a stable foundation for growth investments. The company’s ability to capture GLP-1-driven demand and execute on new product and geographic launches will determine the durability of its new growth trajectory.
- Aon Adoption Is the Linchpin: Early commercial traction validates the platform approach and supports high expectations for 2026 aesthetics growth.
- Operational Leverage Emerging: Flat expenses and improved cash flow signal a scalable model, but margin sustainability will depend on disciplined expansion.
- Watch for Execution on Upside Levers: Timely FDA clearance and international registrations could unlock additional earnings power and expand Apyx’s addressable market meaningfully.
Conclusion
Apyx Medical’s Q4 marked a strategic pivot, with Aon’s launch driving record results and reshaping the company’s long-term outlook. As the business leans into platform integration and GLP-1 market tailwinds, disciplined execution on expansion and innovation will be critical to sustaining momentum and unlocking further upside.
Industry Read-Through
Apyx’s results offer a clear read-through for the broader aesthetics and medical device sector: Integrated platforms that streamline workflow and address emerging patient needs (such as GLP-1-induced skin laxity) are now the growth engine, outpacing legacy single-function devices. The company’s ability to leverage regulatory wins and international expansion will be closely watched by peers, as the market rewards innovation and operational agility. For the wider industry, the shift toward comprehensive, procedure-enabling solutions and recurring revenue models is accelerating—raising the bar for both incumbents and new entrants in the surgical and aesthetics landscape.